CTOs on the Move


 
electroCore is, a US based electroceutical healthcare company, which is developing a range of non-invasive Vagus Nerve Stimulation (nVNS) patient administered therapies for the treatment of multiple conditions in neurology, psychiatry, gastroenterology and other fields. Initial focus is on primary headache (migraine and cluster headache), with trials continuing in epilepsy, gastric motility disorders, depression and anxiety. electroCore, which was founded in 2005, has more than 30 employees and full time consultants with offices in the US (head office), Germany (German and European head office), UK, Italy, Australia, and Canada.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Funding

ElectroCore raised $36M on 09/10/2017
ElectroCore raised $34M on 11/29/2017

Similar Companies

Almost Family

Almost Family is a leading provider of home health nursing, rehabilitation and personal care services. We are a family of companies with names you can trust. For over thirty years, we have been providing skilled compassionate home health care in our local communities. We bring our expertise into the home - the ideal setting to promote healing, comfort and support to those facing the challenges of aging. Our Senior Advocacy philosophy addresses these challenges in a revolutionary new way. Our clinical team looks beyond the obvious needs of the patient to become advocates in all dimensions of physical, mental and emotional well-being. Our goal is to promote independence, allowing seniors to age in place for as long as possible.

Alnylam

Alnylam is the world`s leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today`s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn`t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That`s why we`ve been named a Science Magazine Top Employer for two years in a row (`19-`20), a Boston Globe Top Place to Work 5x in a row (`15-`19) and one of Fast Company`s 50 Most Innovative Companies for 2019. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America.

Vitrolife AB

Vitrolife AB is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Englewood, CO. To find more information about Vitrolife AB, please visit www.vitrolife.com

Trans Life Ambulance

Trans Life Ambulance is a Van Nuys, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Noom

Noom is the world`s leading behavior change company, disrupting the weight loss and healthcare industries. By combining the power of artificial intelligence, mobile tech, and psychology with the empathy of over 1,000 personal coaches, Noom helps people live healthier lives by changing their long-term habits. More than 50 million people have benefited from Noom`s behavior change courses, including its virtual diabetes prevention program, which was the first of its kind to be recognized by the CDC. The Noom platform is already being used by leading healthcare and pharmaceutical companies to improve treatment outcomes for patients worldwide. The company is headquartered in New York City with offices in Seoul and Tokyo.